Full-Time
Sr. Manager/Associate Director
Statistical Programming
Confirmed live in the last 24 hours
Arrowhead Pharmaceuticals
501-1,000 employees
Develops RNAi-based therapies for diseases
Compensation Overview
$160k - $210kAnnually
Senior, Expert
Pasadena, CA, USA + 1 more
- Master degree in Biostatistics or a related field with a minimum of 5-7 years of relevant programming experience in pharmaceutical or biotechnology drug development
- Management experience in statistical programming
- Proficiency in the use of statistical software including SAS, and familiarity of the use of R studio
- Excellent verbal and written communication skills; Effective in communication and team collaboration, influencing across different functional lines
- Understanding and experience with various aspects of a clinical development life-cycle, leading up to regulatory submission and post-approval activities
- Experience interacting with and overseeing programming services of CRO vendors
- Knowledge of cross-functional department functions/roles within a drug development company
- Manage the statistical programming team
- Review of analysis plans for appropriate methodologies
- Review of clinical data as SDTM data sets
- Development of analysis databases (ADaM)
- Programming of study analyses and review of study results;
- Conduct ad-hoc and exploratory statistical analysis and support manuscript preparation
- Communicate the project requirements for cleanup and data capture to ensure the key study variables are suitable for analysis
- Assist in efforts to identify, develop and implement departmental standards, applications, processes and training
- Assist in identifying consultants and the selection of service providers, and oversees statistical and programming deliverables by CROs or service providers
Arrowhead Pharmaceuticals develops medicines aimed at treating severe diseases by targeting and silencing specific genes. The company uses RNA interference (RNAi), a natural process that reduces gene expression, to create therapies that can potentially stop or reverse diseases like cystic fibrosis and hepatitis B. Their approach involves a variety of RNA chemistries and effective delivery methods to ensure that the target genes are significantly reduced in activity. Unlike many competitors, Arrowhead focuses specifically on RNAi-based therapies, which allows them to address medical needs that are not met by existing treatments. The goal of Arrowhead Pharmaceuticals is to provide new treatment options for patients suffering from genetic disorders, leveraging their expertise and partnerships to bring these therapies to market.
Company Stage
IPO
Total Funding
$899.9M
Headquarters
Pasadena, California
Founded
2004
Simplify's Take
What believers are saying
- Arrowhead's recent $450 million funding round provides substantial financial resources to advance its drug pipeline and expand research initiatives.
- Positive Phase 2 data for plozasiran and the initiation of an Expanded Access Program highlight the company's commitment to addressing unmet medical needs.
- The company's diversified pipeline, including treatments for cystic fibrosis, hepatitis B, and myotonic dystrophy, offers multiple avenues for success.
What critics are saying
- The high costs and lengthy timelines associated with drug development could strain Arrowhead's financial resources despite recent funding.
- Regulatory hurdles and the potential for clinical trial failures pose significant risks to the company's drug approval process.
What makes Arrowhead Pharmaceuticals unique
- Arrowhead Pharmaceuticals leverages RNA interference (RNAi) technology to target and silence disease-causing genes, setting it apart from traditional pharmaceutical approaches.
- The company's proprietary TRiM platform enables tissue-specific targeting, enhancing the efficacy and safety of its therapies.
- Strategic partnerships with major pharmaceutical companies like Takeda bolster Arrowhead's credibility and expand its research capabilities.